TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05731986

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Orthostatic challenge
Description: Designed to invoke an orthostatic response. It begins with the participants lying supine on a specialized bed. The bed is then converted into a chair by raising the head of the bed by 90° and dropping the base of the bed by 90° from the knee.~This position will be maintained for 15 minutes, while hemodynamic measures are continuously recorded. Some of these sessions will be accompanied by spinal stimulation.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Orthostatic challenge
Description: Designed to invoke an orthostatic response. It begins with the participants lying supine on a specialized bed. The bed is then converted into a chair by raising the head of the bed by 90° and dropping the base of the bed by 90° from the knee.~This position will be maintained for 15 minutes, while hemodynamic measures are continuously recorded. Some of these sessions will be accompanied by spinal stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biostim-5 transcutaneous spinal stimulation - Mapping
Description: Transcutaneous stimulation of the spinal cord. Two days of mapping will be performed to determine sites for modulation of blood pressure. During each day, with the participant in a supine or seated position, electrodes will be placed on the midline of one of the following spinous processes: C3/4, C5/6, C7/T1, T7/8, T11/12, L1/2 and S1/2. Stimulation intensity will start at 5 mA and gradually increase by 5 mA increments up to 100 mA. The frequency will be two or 30 Hz.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Biostim-5 transcutaneous spinal stimulation - Mapping
Description: Transcutaneous stimulation of the spinal cord. Two days of mapping will be performed to determine sites for modulation of blood pressure. During each day, with the participant in a supine or seated position, electrodes will be placed on the midline of one of the following spinous processes: C3/4, C5/6, C7/T1, T7/8, T11/12, L1/2 and S1/2. Stimulation intensity will start at 5 mA and gradually increase by 5 mA increments up to 100 mA. The frequency will be two or 30 Hz.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biostim-5 transcutaneous spinal stimulation - Optimal testing
Description: Based on the mapping sessions, profiles will be established to guide the selection of an optimal site location for blood pressure modulation (within the range of 110-120 mmHg).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Biostim-5 transcutaneous spinal stimulation - Sham testing
Description: Based on the mapping sessions, a profile that does not elicit a significant blood pressure response, will be used for the sham stimulation.
Study: NCT06345274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Measurement Based Care Training and Monthly Consultation
Description: Participating opioid treatment program leaders and treatment providers will receive two measurement-based care implementation strategies: 1) didactic training including a total of four hours of workshop training led by a measurement-based care expert, and 2) monthly consultation calls led by a measurement-based care expert for 6 months.
Study: NCT05122975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S48168 (ARM210)
Description: Ryanodine Receptor modulator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo of same size and consistency as S48168 (ARM210)
Study: NCT06010160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game Changers for Cervical Cancer Prevention
Description: The peer advocacy training sessions focus on reduction of internalized stigma, disclosure decision making, education on cervical cancer facts and myths, and building skills for cervical cancer prevention advocacy.
Study: NCT05805176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADHD Therapy
Description: investigational game-play therapy
Study: NCT05540132

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: maltodextrin
Description: Pre-exercise carbohydrate, fast-acting

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: super starch
Description: Pre-exercise carbohydrate, slow-acting
Study: NCT05082857

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional Parents as Teachers (PAT)
Description: A twice-a-month home visits from trained family educators. Home visits will continue for the remainder of the study period as will the other components of the Parents as Teachers model: regular Group Connections for peer interactions and support, age-appropriate health and developmental screenings, and referrals that reflect mother and infant needs to community agencies that include the Child Development Services Agency (which provides screening for Individuals with Disabilities in Education Act (IDEA) Part C services), family services, intensive mental health services, among others.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hybrid PAT model
Description: A six-week virtual evidence-based parenting class entitled What You Do Matters, which will be delivered in partnership with the Pediatric Advocacy Program at WFBMC which combines short parent-educator discussions followed by interactive activities and peer to peer networking.
Study: NCT06279000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine Group:~IMP = Colchicine (0.5 mg, enteral) first application in the evening before day of surgery, following a 1-0-1 regimen until the third postoperative day, ending with the application of the ninth dose. Colchicine tablets are provided as 1 mg tablets with a score, which must be divided before ingestion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Group:~Placebo (identical to IMP in appearance and application) first application in the evening before day of surgery, following a 1-0-1 regimen until the third postoperative day, ending with the application of the ninth dose. Placebo tablets are provided as tablets with a score, which must be divided before ingestion.
Study: NCT05867407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anumana Low EF AI-ECG Algorithm
Description: Clinician will have access to the Anumana Low EF AI-ECG algorithm via a link in the patient's electronic health record which will display results applied to patients' ECGs, as well as supporting information. Using the results of the algorithm, combined with the clinician's knowledge of patient-specific risk factors, the clinician will determine whether further evaluation is warranted.

Intervention type: OTHER
Group type: OTHER
Intervention: Care-as-Usual
Description: Clinicians will not have access to the Anumana Low EF AI-ECG algorithm and will provide care-as-usual.
Study: NCT05224973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: speech therapy
Description: speech therapy during 2 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: speech therapy
Description: speech therapy during 2 months
Study: NCT05076006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: Active study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator
Study: NCT06139510

Intervention type: OTHER
Group type: OTHER
Intervention: Quantitative sensory testing
Description: Quantitative sensory testing is a standard type of pain testing that measures changes in sensitivity to different type of sensations that include temperature, touch or pressure.
Study: NCT05261646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Description: Stage 1： Hetrombopag lower dose； Hetrombopag higher dose~Stage 2:~Hetrombopag X mg (dose to be determined based on Stage 1 results)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo（Stage 1；Stage 2）
Study: NCT06326814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humanized anti-Factor Bb monoclonal antibody
Description: Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humanized anti-Factor Bb monoclonal antibody
Description: Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humanized anti-Factor Bb monoclonal antibody
Description: Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humanized anti-Factor Bb monoclonal antibody
Description: Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humanized anti-Factor Bb monoclonal antibody
Description: Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humanized anti-Factor Bb monoclonal antibody
Description: Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humanized anti-Factor Bb monoclonal antibody
Description: Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration
Study: NCT06008314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePNa
Description: Real-time, automated clinical decision support tool for pneumonia (called ePNa)
Study: NCT05187689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR + MHL intervention
Description: The intervention will include: 1) a Virtual Reality (VR) interactive and immersive 30-minute session viewed using a low cost VR headset; and 2) an 8-week program of weekly WelTel SMS check-ins managed by Peer Navigators (PNs), weekly WelTel SMS blasts informed by Psychological First Aid (PFA) with mental health literacy (MHL) messages developed with PN, and weekly WelTel web-based secure platform social group discussions on MHL, stress coping, and stigma moderated by PN alongside a trained Coordinator. Weekly MHL WelTel platform moderated discussion foci will address MHL, stigma and stress coping strategies, including self-compassion and other strategies that emerge from the urban refugee youth interviews and focus groups, through diverse methods, including: 'scenarios' mimicking real life situations; a 'question box'; sharing photos demonstrating stress coping strategies; memes; songs; and ways participants interrupted stigma in their daily lives.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group PM+
Description: Participants will attend small groups (5-6 participants with a PN and a coordinator supporting) outdoors with physically distancing, for Group PM+ sessions following the adapted WHO Group-PM+ manual (adaptations made in Phase 1 explain above) 5 weekly 3-hour sessions delivered by PN who will co-facilitate sessions with the Coordinator. Each session has a mechanism of action:~1. Managing stress: mechanism of action-identify goals, learn deep breathing and techniques for stress management~2. Managing problems: mechanism of action-identify 1 solvable practical problem, brainstorm possible solutions together~3. Get going, keep doing: mechanism of action-learn about depression and inactivity, identify and plan small enjoyable activities~4. Strengthen social support: mechanism of action-discuss a range of social support resources, make plan to increase social support~5. Staying well: mechanism of action- this session reviews all of the mechanisms of action in the prior 4 sessions
Study: NCT04126135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: Subjects will take a 25-day course of Cytisine tablets started during the 4 days before the quit date. They will be asked to reduce smoking during this time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Description: Subjects are asked to completely stop smoking on their quit day and use a daily NRT patch for 25 days.
Study: NCT05408429

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20-valent pneumococcal conjugate vaccine
Description: 20-valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20-valent pneumococcal conjugate vaccine
Description: 20-valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 13-valent pneumococcal conjugate vaccine
Study: NCT04825678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered as a subcutaneous injection via the SureClick® Autoinjector Pen (AI/Pen).
Study: NCT05737069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen arginine granules 400 mg
Description: Experimental- Ibuprofen arginine granules 400 mg, one sachet administration containing 400 mg ibuprofen granules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen arginine granules 400 mg
Description: Experimental- Ibuprofen arginine granules 400 mg, one sachet administration containing 400 mg ibuprofen granules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen arginine granules 400 mg (Spedifen)
Description: Marketed drug- Ibuprofen arginine granules 400 mg (Spedifen), one sachet administration containing 400 mg ibuprofen granules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen arginine granules 400 mg (Spedifen)
Description: Marketed drug- Ibuprofen arginine granules 400 mg (Spedifen), one sachet administration containing 400 mg ibuprofen granules.
Study: NCT06135805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinonide 0,05% oral gel
Description: Application of Fluocinonide oral gel on oral syntomatic lesions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of placebo oral gel on oral lesions
Study: NCT06565962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educaiton group
Description: The experimental group will be made to watch training videos prepared by AFAD on disaster preparedness, disaster moment and post-disaster by using virtual reality goggles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: No intervention will be performed in the control group.
Study: NCT05144373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gross motor intervention, gross and fine motor intervention
Description: For gross motor intervention, participants will receive a home-based, parent-administered body-weight supported treadmill intervention from about 10 months of age until walking onset.~For gross and fine motor intervention, participants will receive the same treadmill intervention as illustrated above. In addition, participants will receive a fine motor intervention with practice of reaching and grasping using sticky mittens from about 10 months of age for five months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gross motor intervention, gross and fine motor intervention
Description: For gross motor intervention, participants will receive a home-based, parent-administered body-weight supported treadmill intervention from about 10 months of age until walking onset.~For gross and fine motor intervention, participants will receive the same treadmill intervention as illustrated above. In addition, participants will receive a fine motor intervention with practice of reaching and grasping using sticky mittens from about 10 months of age for five months.
Study: NCT05106647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduce screen time
Description: The intervention is information provided via email on how to set up an automated response to emails received during their weekend off, reduce screen time for duration of leisure time, and uninstall work applications from their mobile device.
Study: NCT06091111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THD, THN
Description: New hybrid absorbing incontinence product for day (THD) and night (THN) use. These are variants of the same product. The intervention product is a novel design that contains reusable elements allowing for a more sustainable product.
Study: NCT05306899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Bolus of IV Ketamine 1 mg.kg-1 (= 0.1 ml.kg-1) followed by Infusion of Ketamine 1 mg.kg-1.hour-1 (= 0.5 mL.kg-1.hour-1) for 6 hours. All patients will receive IV midazolam 0.04 mg.kg-1 (maximum 3 mg) and subsequently 0.01-0.02 mg.kg-1 every hour to keep participants in a sedated but arousable state (Ramsay Sedation Scale score 3 or 4) to blind the participants and assessors to group allocation. Ondansetron 8 mg and 8 mg of dexamethasone will be administered to prevent nausea, 5000 units of heparin will be given subcutaneously to prevent thrombo-embolic events.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Bolus of IV Saline 0.9% of 0.1 ml.kg-1 followed by Infusion of Saline 0.9% of 0.5 mL.kg-1.hour-1 for 6 hours. All patients will receive IV midazolam 0.04 mg.kg-1 (maximum 3 mg) and subsequently 0.01-0.02 mg.kg-1 every hour to keep participants in a sedated but arousable state (Ramsay Sedation Scale score 3 or 4) to blind the participants and assessors to group allocation. Ondansetron 8 mg and 8 mg of dexamethasone will be administered to prevent nausea, 5000 units of heparin will be given subcutaneously to prevent thrombo-embolic events.
Study: NCT05708755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus T Cell Immunity Panel (CMV-TCIP)
Description: Whole blood assay that evaluates T cell (CD4 and CD8) responses to cytomegalovirus (CMV) antigens via intracellular cytokine staining (ICS).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Donor-Derived Cell-Free DNA (dd-cfDNA) Assay
Description: Determines the percentage of circulating cell-free DNA (cfDNA) in transplant recipients derived from donor grafts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Delivered as standard of care for post-lung transplant immunosuppression and infection prophylaxis. Started on the first day post-transplant at a standard dose of 900 mg daily and continued for 12 months. Dose adjustments may be necessary based on renal function and/or adverse effects (e.g. neutropenia). Dose adjustments are standard based on package insert recommendations.
Study: NCT05473364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Diuretic and carbonic anhydrase inhibitor medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Diuretic and carbonic anhydrase inhibitor medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Diuretic and carbonic anhydrase inhibitor medication
Study: NCT06281925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy Gloves
Description: All patients in the intervention group will receive cryotherapy with cold packs enclosed in a fabric envelope (gloves). The fabric envelope (gloves) will be patient specific.
Study: NCT06212856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training
Description: The group will receive plyometric exercises in a controlled environment. Following, Plyometrics would be performed.~1. Leg hops~2. Tuck jumps~3. Vertical jumps~4. Explosive push-ups~5. Jumping spider~6. Lateral/ diagonal and broad jumps~7. Clapping push-ups~8. Medicine ball presses~9. Rotational throws~10. Vertical and obstacle jumps~11. Box shuffles~12. Chest passes~13. Box jumps~14. Drop jumps~15. Overarm throws

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional
Description: The group will receive conventional exercises in a controlled environment. Following, conventional exercises would be performed.~1. Pushups.~2. Situps.~3. Lunges~4. Squats~5. 500m running
Study: NCT06235190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Felix NeuroAI Wristband
Description: The Felix NeuroAI Wristband (Felix) is a wrist-worn, noninvasive, transcutaneous neurostimulation system. Using a proprietary artificial intelligence (AI) algorithm, stimulation will be automatically adapted to patient's needs with the goal to provide full day relief of upper limb tremor.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: The sham device has the same exterior appearance and components as the Felix device and is used the same way (without delivering the treatment).